HSBC AKT.ANL. 06/24 SNW/ DE000HS1UF59 /
04/06/2024 19:40:10 | Chg.+0.250 | Bid21:20:39 | Ask21:20:39 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
91.220EUR | +0.27% | 90.870 Bid Size: 50,000 |
91.070 Ask Size: 50,000 |
SANOFI SA INHABER ... | 100.00 EUR | 28/06/2024 | Call |
GlobeNewswire
13:00
CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Pres...
GlobeNewswire
12:00
FutureBrand Consumer Index Reveals Brands Are Missing Key Growth Opportunities and Falling Short on ...
GlobeNewswire
03/06
Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival ...
GlobeNewswire
31/05
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GlobeNewswire
31/05
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
GlobeNewswire
31/05
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...
GlobeNewswire
31/05
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...
GlobeNewswire
27/05
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible ...
GlobeNewswire
21/05
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
GlobeNewswire
20/05
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire
20/05
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire
20/05
Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meet...
GlobeNewswire
13/05
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire
13/05
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
GlobeNewswire
13/05
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...